Race Oncology Ltd. ( (AU:RAC) ) has provided an update.
Race Oncology has initiated its first Australian clinical site at Southside Cancer Care Centre in Miranda, NSW, for a Phase 1 trial of RC220 in combination with doxorubicin for advanced solid tumours. This trial, which will be conducted across multiple sites in Australia, Hong Kong, and South Korea, aims to evaluate the safety, pharmacokinetics, and maximum tolerated dose of RC220, while also assessing its cardioprotective and anticancer efficacy. The initiation marks a significant step towards Race’s mission to provide innovative cancer treatments, with the trial designed to offer flexibility and speed through a Bayesian approach. The company plans to provide regular updates on the trial’s progress.
More about Race Oncology Ltd.
Race Oncology (ASX: RAC) is a clinical stage biopharmaceutical company focused on cancer care. The company is advancing bisantrene, a chemotherapeutic with a unique clinical history, as its lead asset. Bisantrene is known for its anticancer effects and reduced cardiotoxicity compared to other anthracyclines. Race is developing RC220, a reformulated version of bisantrene, to address unmet needs in oncology, particularly in anthracycline combinations for solid tumours and as a treatment for acute myeloid leukaemia. The company is also exploring the effects of bisantrene on the m6A RNA pathway, which is implicated in various cancers.
YTD Price Performance: -19.26%
Average Trading Volume: 91,524
Technical Sentiment Signal: Buy
Current Market Cap: A$189.4M
See more insights into RAC stock on TipRanks’ Stock Analysis page.